AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01528800
Drug: Vitamin K1
RxNorm normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg orally three times a week for 12 months
Trial: NCT01528800
Drug: Microcrystalline Methylcellulose
RxNorm normalized name: Methylcellulose
DrugBank: Methylcellulose (DB11228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg orally three times a week for 12 months
Trial: NCT04102189
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive semaglutide s.c. once weekly for a dose escalation period of 16 weeks and a maintenance period of 52 weeks
Trial: NCT00362063
Drug: growth hormone (Nutropin)
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: growth hormone (Nutropin), 0.3mg/kg/week administered subcutaneously daily.
Trial: NCT00791713
Drug: Paliperidone ER
RxNorm normalized name: Paliperidone ER
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04601142
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: methylprednisolone pulse therapy: 500-1000mg/d，３-５ｄ
Trial: NCT02932475
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1000 mg twice a day
Trial: NCT00296959
Drug: topiramate (drug)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00052169
Drug: ZD1839 in combination with docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel given as 75 mg/m2 IV every 3 weeks combined with ZD1839 (IRESSA) 250 mg orally daily until disease progression or withdrawal criteria are met.
Trial: NCT00102505
Drug: Motexafin Gadolinium Injection
RxNorm normalized name: gadolinium
DrugBank: Motexafin gadolinium (DB05428)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00367497
Drug: Rituximab, Etoposide, Methylprednisolone, Cytarabine, Cisplatin
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01323257
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg tablet once daily for 7 days (Trt E, F)
Trial: NCT01323257
Drug: Darunavir
RxNorm normalized name: Darunavir
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 x 400 mg tablet once daily for 7 days (Trt E, F)
Trial: NCT01831973
Drug: Lipotecan
RxNorm normalized name: Lipotecan
DrugBank: Lipotecan (DB17385)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01452126
Drug: Ropivacaine concentration
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single shot preoperative perineural injection of ropivacaine to achieve surgical anesthesia. The concentration of ropivacaine is lowered by 0.05% after every successful surgical anesthesia specific to that block and raised by 0.05% after every unsuccessful surgical anesthesia specific to that block
Trial: NCT03220048
Drug: PrEP-001
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03587558
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in this group are taking carvedilol to inhibit outflow tract PVC/VT.
Trial: NCT03587558
Drug: Flecainide
RxNorm normalized name: Flecainide
DrugBank: Flecainide (DB01195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in this group are taking flecainide to inhibit outflow tract PVC/VT.
Trial: NCT03414840
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients diagnosed with coronary artery disease by CCTA be enrolled. Among enrolled patients, patients who is indicated to statin treatment according to the current ACC/AHA guideline will be treated with atorvastatin.
Trial: NCT03462446
Drug: Rivaroxaban (Xarelto, BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: As prescribed by treating physicians
Trial: NCT02476981
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receiving dexmedetomidine were given that drug at 0.3-0.4 µg/kg over 10 min, followed by continuous infusion of 0.2 1 µg/kg/h
Trial: NCT02476981
Drug: midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients were premedicated with midazolam 0.02 mg/kg before induction.
Trial: NCT02476981
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients in both groups received a bolus dose of propofol 0.3 mg/kg for sedative effect.
Trial: NCT02476981
Drug: ephedrine
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ephedrine 5 mg was injected when systolic blood pressure decreased below 90 mmHg
Trial: NCT01689207
Drug: Avibactam (AVI)
DrugBank: Avibactam (DB09060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PART A: AVI IV infusion
Trial: NCT01689207
Drug: Aztreonam (ATM)
RxNorm normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PART A: ATM IV infusion
Trial: NCT01689207
Drug: combination of Aztreonam - Avibactam (ATM-AVI)
RxNorm normalized name: avibactam / aztreonam
DrugBank: Aztreonam (DB00355)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PART A: ATM-AVI IV infusion. PART B and C: ATM-AVI IV infusions.
Trial: NCT01801137
Drug: Everolimus (Afinitor®)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00364845
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose was calculated at 0.75 micrograms per kilogram (μg/kg) body weight at randomization, rounded to nearest prefilled syringe dose unit. Dose was titrated incrementally. Monthly dose was initially double the every 2 week dose at time of conversion.
Trial: NCT02058927
Drug: Measles vaccine
RxNorm normalized name: Measles vaccine
DrugBank: Measles virus vaccine live attenuated (DB10315)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: measles revaccination administered at 12 months from start of ART
Trial: NCT01529476
Drug: Levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: levofloxacin 500 mg,QD,7\~10 days
Trial: NCT01529476
Drug: Nemonoxacin
RxNorm normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemonoxacin 500mg,QD,7\~10 days
Trial: NCT00267280
Drug: torcetrapib/atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02624401
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT02624401
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT02624401
Drug: S-ketamine
RxNorm normalized name: S-ketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous infusion
Trial: NCT02624401
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhalation
Trial: NCT01438567
Drug: oxycodone/naloxone prolonged release (OXN PR) tablets
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug: Oxycodone/naloxone prolonged release tablets Arms: OXN PR Dosage: 2x50/25mg daily or 2x60/30mg daily or 2x70/35mg daily or 2x80/40mg daily
Trial: NCT01438567
Drug: oxycodone prolonged release (OxyPR) tablets
RxNorm normalized name: oxycodone Extended Release Oral Tablet
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug: Oxycodone prolonged release tablets Arms: OxyPR Dosage: 2x50mg daily or 2x60mg daily or 2x70mg daily or 2x80mg daily
Trial: NCT00649467
Drug: Topiramate Sprinkle Capsules 25 mg
RxNorm normalized name: topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25mg, single dose applesauce
Trial: NCT01196169
Drug: Daptomycin
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One dose of Daptomycin 6 mg/Kg iv, will be infused over 30 minutes. The infusion will start no longer than one hour prior to surgical incision of primary knee or hip prosthetic joint arthroplasty.
Trial: NCT01196169
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two doses of vancomycin 15 mg/Kg iv, with a maximum of 2 grams with each dose be infused over 60-120 minutes according to the dose. The first dose infusion will start no longer than one hour (if ≤ one gram), or no longer than two hours (if \> one gram) prior to surgical incision of primary knee or hip prosthetic joint arthroplasty. A second similar dose will be given 12 hours after the first dose unless the patient has a creatinine clearance of \< 50 ml/min. Patients with creatinine clearance of \< 50 ml/min will only receive one dose.
Trial: NCT02426658
Drug: Pemetrexed Disodium
RxNorm normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT00088634
Drug: Lurasidone
RxNorm normalized name: Lurasidone
DrugBank: Lurasidone (DB08815)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 80 mg AM dosing once daily
Trial: NCT02150824
Drug: BI 187004
RxNorm normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 187004 high dose once daily add on to background metformin
Trial: NCT02150824
Drug: BI 187004
RxNorm normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 187004 medium dose once daily
Trial: NCT02150824
Drug: BI 187004
RxNorm normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 187004 low dose once daily
Trial: NCT02150824
Drug: BI 187004
RxNorm normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 187004 high dose once daily
Trial: NCT00524316
Drug: sunitinib malate
RxNorm normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given Orally
Trial: NCT02619019
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 8 mg of dexamethasone intrathecally
Trial: NCT02619019
Drug: Pethidine
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 0.2 mg/kg of pethidine intrathecally
Trial: NCT04035135
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: investigational drug
Trial: NCT01402284
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cycle 1: 20 mg/m(2) intravenous (IV) infusion over 30 minutes on days 1 and 2, then 36 mg/m(2) IV on days 8, 9, 15, and 16 Cycle 2-8: 36mg/ m(2) IV infusion over 30 minutes on days 1, 2, 8, 9, 15, and 16
Trial: NCT01402284
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cycle 1: 25 mg oral days 2-21 of 28-day cycle; Cycle 2 - 8: 25 mg oral days 1-21 of 28-day cycle; After 8 cycles of combination carfilzomib, lenalidomide, and dexamethasone (CRd), patients may continue Lenalidomide for 12 cycles; After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year
Trial: NCT01402284
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cycle 1: 20 mg oral or IV on days 2, 8, 9, 15, 16, 22, and 23 Cycle 2-4: 20 mg oral or IV on days 1, 2, 8, 9, 15, 16, 22, and 23 Cycle 5-8: 10 mg oral or IV on days 1, 2, 8, 9, 15, 16, 22, and 23
Trial: NCT01402284
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: After 8 cycles of combination carfilzomib, lenalidomide, and dexamethasone (CRd), patients may continue Lenalidomide for 12 cycles
Trial: NCT01402284
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year
Trial: NCT01592279
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01592279
Drug: Insulin injections
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04666324
Drug: Simethicone Solution
RxNorm normalized name: Simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral daily treatment for four weeks
Trial: NCT01803763
Drug: Omalizumab (Xolair)
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fixed dose of 300 mg omalizumab is subcutaneously administered in total 4 monthly doses
Trial: NCT02929563
Drug: Pantoprazole
RxNorm normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03638726
Drug: Topical cyclopentolate and phenylephrine
RxNorm normalized name: cyclopentolate / phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm: Preoperative cyclopentolate and phenylephrine eye drops are used.
Trial: NCT01199263
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT04552535
Drug: Second line (2L) afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib
Trial: NCT02928406
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab 1200 milligrams (mg) will be administered by intravenous (IV) infusion Q3W.
Trial: NCT00004013
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00086957
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2 every three weeks, or 60 mg/m2 every three weeks depending on study findings
Trial: NCT00086957
Drug: gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg daily or 250 mg daily on days 2 through 14 depending on study findings
Trial: NCT00894413
Drug: Tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg once daily for 10 - 14 days
Trial: NCT01919788
Drug: Insulin (Insuman Rapid)
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01919788
Drug: Glucose
RxNorm normalized name: Glucose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03962283
Drug: Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin 200mcg four times daily
Trial: NCT03890887
Drug: BI 1291583
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT03890887
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT00443339
Drug: Darbepoetin
RxNorm normalized name: Darbepoetin
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02531035
Drug: Sotagliflozin
RxNorm normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Sotagliflozin, once daily, before the first meal of the day
Trial: NCT00620321
Drug: LY2181308 sodium
RxNorm normalized name: LY2181308
DrugBank: LY2181308 (DB05141)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 milligrams (mg) is administered as a 3-hour intravenous infusion on Days 1, 2, 3, 8, 15, 22 of Cycle 1 (28 days) and Days 1, 8, 15, 22 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
Trial: NCT03133312
Drug: Chlorhexidine Gluconate
RxNorm normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative vaginal preparation with 4% Chlorhexidine Gluconate Intervention
Trial: NCT00620321
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1.5 grams per square meter (g/m²) will be administered as a 4-hour intravenous infusion on Days 3, 4, 5 of Cycle 1 (28 days) and Days 1, 2, 3 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
Trial: NCT00620321
Drug: idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 milligrams per square meter (mg/m²) will be administered as a 30-minute intravenous infusion on Days 3, 4, 5 of Cycle 1 (28 days) and on Days 1, 2, 3 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
Trial: NCT02563288
Drug: Esmolol
RxNorm normalized name: Esmolol
DrugBank: Esmolol (DB00187)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: effect of esmolol on intraoperative sympathetic control and on extubation conditions.
Trial: NCT02563288
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: effect of dexmedetomidine on intraoperative sympathetic control and on extubation conditions.
Trial: NCT01240811
Drug: IUD placement
RxNorm normalized name: copper
DrugBank: Copper (DB09130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volunteer subjects who are not at risk of pregnancy because they are either surgically sterilized or heterosexually abstinent will be enrolled into the control group (no intervention). All other volunteers will be seeking an IUD for contraception and will be randomized to LNG-IUD (Mirena) or Copper IUD (ParaGard).
Trial: NCT01240811
Drug: Levonorgestrel IUD
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01240811
Drug: Copper T380A IUD
RxNorm normalized name: copper
DrugBank: Copper (DB09130)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02898207
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT02898207
Drug: Onalespib
RxNorm normalized name: Onalespib
DrugBank: Onalespib (DB06306)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03133312
Drug: Povidone-Iodine Scrub and Paint
RxNorm normalized name: Povidone-Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative vaginal preparation with 10% Povidone-Iodine Scrub and Paint Intervention
Trial: NCT00119301
Drug: trimetrexate glucuronate
RxNorm normalized name: Trimetrexate Glucuronate
DrugBank: Trimetrexate (DB01157)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02380352
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04484779
Drug: Insulin Lispro and/or Insulin Glargine
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered subcutaneously (SC)
Trial: NCT02391844
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone with Acetaminophen Extended Release
Trial: NCT00162396
Drug: Albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00656266
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: immunosuppresion medication called mycophenolate mofetil, also known as MMF or CellCept
Trial: NCT02410902
Drug: CM-AT
RxNorm normalized name: rose bengal AT
DrugBank: Rose bengal (DB11182)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
Trial: NCT04940559
Drug: Danicopan - Tablet
RxNorm normalized name: Danicopan
DrugBank: Danicopan (DB15401)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet.
Trial: NCT04940559
Drug: Danicopan - Softgel
RxNorm normalized name: Danicopan
DrugBank: Danicopan (DB15401)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral softgel capsule.
Trial: NCT02322892
Drug: Normal saline solution
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mL normal saline once immediately before surgery and once immediately after (at arrival in the intensive care unit)